Late-stage Biopharmaceutical Company Granted FDA Approval For Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation to Soligenix, Inc. (NASDAQ: SNGX) for their pioneering treatment, SuVax™. This treatment is aimed at the prevention and post-exposure prophylaxis of Sudan Ebolavirus infection, a critical unmet medical need that poses a global health threat. Soligenix, a late-stage biopharmaceutical company, is at the forefront of developing and commercializing products to treat rare diseases where the current medical response is insufficient. Their innovative SuVax™ vaccine stands out as a beacon of hope against Sudan Virus Disease, caused by the Sudan Ebolavirus, for which no treatment or vaccine is currently available. $Soligenix(SNGX.US)$